Guselkumab news

All news on Guselkumab (also known as TREMFYA): plants, production capacities, investments and involved companies.

28 May 2026

Johnson & Johnson: FDA approves TREMFYA label update for PsA joint‑damage inhibition

APEX Phase‑3b: in biologic‑naïve PsA patients, 24‑week results met ACR20 and significantly inhibited structural joint damage vs placebo; placebo switchers had 57% less radiographic progression to Week 48; safety unchanged.
21 February 2026

Johnson & Johnson's TREMFYA® Shows Sustained Remission in Ulcerative Colitis Over 3 Years

TREMFYA® maintains clinical, endoscopic, and histologic outcomes in ulcerative colitis through 140 weeks, with high patient retention and no new safety concerns.
22 December 2025

EC Approves Johnson & Johnson's TREMFYA® for Treating Plaque Psoriasis in Children

TREMFYA® gains EC approval for treating moderate to severe plaque psoriasis in children, marking the first IL-23 inhibitor for pediatric use.

Who will be producing Guselkumab in the future?

Find out with chemXplore Alpha

Learn more